|
|
 |
|
Viewing report
|
|
|
|
Asia Pacific Markets for Orthopedic Biomaterials 2011 – Bone Grafting and Hyaluronic Acid Viscosupplementation
iData Research, July 2011, Pages: 358
The Asia-Pacific orthopedic biomaterials market is expected to approach $1.6 billion by 2017. The hyaluronic acid viscosupplementation segment is expected to constitute the majority of the Asia-Pacific orthopedic biomaterials market.
The Asia-Pacific orthopedic biomaterials report covers the following countries:
- Japan
- South Korea
- Australia
- China
The segments covered in this report include:
- autologous bone grafts,
- bone graft substitutes (BGS; segmented into allografts, demineralized bone matrices and synthetics),
- hyaluronic acid (HA) viscosupplementation,
- bone morphogenetic protein (BMP) growth factor therapy
- autologous chondrocyte implantation (ACI)
The market is approaching maturity, but is expected to continue to grow as a result of the aging Asia-Pacific population. BMP growth factor therapy was the fastest growing segment in 2010, increasing almost 7% over the previous year.
This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2017, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.
The executive summary of this report is also available for purchase.
Also available
Asia Pacific Markets for Orthopedic Biomaterials 2011 – Bone Grafting and Hyaluronic Acid Viscosupplementation (Executive Summary)
|
|
|
|
